Medicine recalls
|
| |
| The United States: Adamis Pharmaceuticals Corporation issues nationwide voluntary recall of SYMJEPI (epinephrine) Injection for potential manufacturing defect |
| |
The US Food and Drug Administration (FDA) announces that Adamis Pharmaceuticals Corporation is voluntarily recalling certain lots of SYMJEPI (epinephrine) Injection pre-filled single-dose syringes to the consumer level. The lots are being recalled due to the potential clogging of the needle preventing the dispensing of epinephrine. SYMJEPI is manufactured and tested for Adamis by Catalent Belgium S.A. The affected products are:
- SYMJEPI (epinephrine) Injection 0.15 mg/0.3 ml (lot number: 21101Y)
- SYMJEPI (epinephrine) Injection 0.3 mg/0.3 ml (lot number: 21041W, 21081W, 21102W)
If a person is experiencing an allergic reaction and/or anaphylaxis and is unable to access life-saving epinephrine due to the syringe malfunction, it can lead to life threatening consequences including death. Although not confirmed to be related to the recall, there have been two different customer complaints on three syringes, regarding difficulty in dispensing the product, to date. However, neither US WorldMeds (exclusively markets and distributes SYMJEPI in the United States) nor Adamis has received, or is aware of, any adverse events related to this recall.
Please refer to the following website in FDA for details:
http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/adamis-pharmaceuticals-corporation-issues-nationwide-voluntary-recall-symjepir-epinephrine-injection
In Hong Kong, the above products are not registered pharmaceutical products.
Ends/Wednesday, Mar 23, 2022
Issued at HKT 15:30
|
| |
